The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $61.77

Today's change+1.03 +1.70%
Updated November 21 1:18 PM EST. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $61.77

Today's change+1.03 +1.70%
Updated November 21 1:18 PM EST. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc up sharply

Intercept Pharmaceuticals Inc is up sharply today, rallying (U.S.)$1.03 or 1.70% to (U.S.)$61.77. Over the last five days, shares have gained 5.32%, but are down 43.15% for the last year to date. Shares have underperformed the S&P 500 by 64.66% during the last year.

Key company metrics

  • Open(U.S.) $61.19
  • Previous close(U.S.) $60.74
  • High(U.S.) $62.29
  • Low(U.S.) $60.27
  • Bid / Ask(U.S.) $61.76 / (U.S.) $61.91
  • YTD % change-43.15%
  • Volume331,827
  • Average volume (10-day)737,633
  • Average volume (1-month)918,754
  • Average volume (3-month)1,317,996
  • 52-week range(U.S.) $54.98 to (U.S.) $135.59
  • Beta-2.00
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$14.80
Updated November 21 1:18 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-344.74%

Although this company's net profit margin is negative, it is above the industry average and implies that Intercept Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.45%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue41312114
Total other revenue--------
Total revenue41312114
Gross profit413121--
Total cost of revenue000--
Total operating expense108111105128
Selling / general / administrative61676197
Research & development46444431
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-66-81-84-114
Interest income (expense), net non-operating-7-7-7-7
Gain (loss) on sale of assets--------
Other--------
Income before tax-73-87-90-120
Income after tax-73-87-90-120
Income tax, total--------
Net income-73-87-90-120
Total adjustments to net income--------
Net income before extra. items-73-87-90-120
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-73-87-90-120
Inc. avail. to common incl. extra. items-73-87-90-120
Diluted net income-73-87-90-120
Dilution adjustment----0--
Diluted weighted average shares25252525
Diluted EPS excluding extraordinary itemsvalue per share-2.89-3.46-3.61-4.84
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-2.89-3.46-3.61-4.84